Abstract Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …

IgM monoclonal gammopathy of undetermined significance is a pre-malignant condition for
Waldenström macroglobulinemia and other B-cell malignancies, defined by asymptomatic …

PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study
showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM) …

PURPOSE BCL2 is overexpressed and confers prosurvival signaling in malignant
lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent …

Abstract Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …

Scope The objective of this guideline is to provide healthcare professionals with clear
guidance on the management of patients with Waldenström macroglobulinaemia. In …

Cold antibody-mediated autoimmune hemolytic anemia (cAIHA) is a rare disease, usually
related to an underlying indolent clonal B-cell lymphoproliferative disorder. Jalink and …

Autoimmune diseases of the peripheral nervous system have so far been treated mainly with
exogenous high-dose intravenous immunoglobulins (IVIg), that act through several …

Background Orelabrutinib is a novel, small molecule, selective irreversible Bruton tyrosine
kinase inhibitor. The purpose of this study was to evaluate the efficacy and safety of …

PURPOSE Rituximab/chemotherapy is a cornerstone of treatment for Waldenström's
macroglobulinemia (WM). In addition, bortezomib has shown significant activity in WM. This …